Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...
PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of ...
Procept Biorobotics is a top performer in the medical device industry, offering relief for men with BPH. The company's minimally invasive procedure is experiencing rapid growth in both system sales ...
PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares have had a really impressive month, gaining 32% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since the share ...
The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...
REDWOOD SHORES, Calif.--(BUSINESS WIRE)--PROCEPT BioRobotics announced today that it raised $118 million in an equity financing led by new investor Viking Global Investors LP, with participation from ...
In the latest quarter, 6 analysts provided ratings for PROCEPT BioRobotics (NASDAQ:PRCT), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...
Throughout the last three months, 7 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of ...
On Thursday, Spruce Point Capital released a detailed report on PROCEPT BioRobotics (NASDAQ:PRCT), raising concerns about the claims surrounding its market potential and growth prospects, suggesting ...
Hosted on MSN
Oppenheimer Initiates Coverage of PROCEPT BioRobotics (PRCT) with Perform Recommendation
Fintel reports that on July 7, 2025, Oppenheimer initiated coverage of PROCEPT BioRobotics (NasdaqGM:PRCT) with a Perform recommendation. Analyst Price Forecast Suggests 40.25% Upside As of June 20, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback